Maiwei Bio said its internally developed antibody candidate 9MW5211 received
approval from China’s NMPA to start clinical trials for multiple sclerosis (MS).
9MW5211 previously won clearance in China and the US to enter trials for
inflammatory bowel disease (IBD). Applications to test additional indications
are underway.